| Methods |
ITS |
| Participants |
Setting: Canada, Quebec |
| Interventions |
Ceiling + Co‐insurance |
| Outcomes |
Medicine use |
| Notes |
Supported by Grant of the Medical Research Council of Canada, Eli Lilly Canada, Inc., Merck Frosst Canada, Inc., Pfizer Canada, Inc. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not applicable (ITS) |
| Allocation concealment (selection bias) |
Unclear risk |
Not applicable (ITS) |
| Baseline outcome measurement similarity |
Unclear risk |
Not applicable (ITS) |
| Baseline characteristics similarity |
Unclear risk |
Not applicable (ITS) |
| Protection against contamination |
Unclear risk |
Not applicable (ITS) |
| Intervention independent of other changes |
Low risk |
Intervention was independent of other relevant changes |
| Shape of the intervention effect pre‐specified |
Low risk |
Point analysis is the point of intervention |
| Intervention unlikely to affect data collection |
Low risk |
Sources and methods were the same before and after the intervention |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
No outcome measures are missing |
| Blinding of outcome assessment (detection bias)
All outcomes |
Low risk |
Outcomes are objective |
| Selective reporting (reporting bias) |
Low risk |
All relevant outcomes in the Methods section are reported in the Results section |
| Other bias |
Low risk |
No other important bias is detected in the study |
